Prokidney Announces Proposed $125 Million Public Offering Of Class A Ordinary Shares And Concurrent Registered Direct Offering

( MENAFN - GlobeNewsWire - Nasdaq) WINSTON-SALEM, N.C., June 10, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp.

(Nasdaq: PROK) (“ProKidney” or the“Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease, today announced that it has commenced an underwritten public offering and a concurrent registered direct offering of up to an aggregate of $125 million of its Class A ordinary shares, before deducting underwriting discounts and commissions and other offering expenses. ProKidney expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the Class A ordinary shares sold in the underwritten public offering. All of the Class A ordinary shares in the underwritten public offering and concurrent registered direct offering are being sold by the Company.

Certain investment entities, which includes entities affiliated with the Company's chairman and holders of more than 10% of the Company's outstanding capital stock, have expressed an interest in purchasing the Company's Class A ordinary shares in the offering. These entities may purchase in either the underwritten public offering or in the concurrent registered direct offering. However, because indications of interest are not binding agreements or commitments to purchase, the Company and the underwriters could determine to sell more, fewer or no shares to any of these potential purchasers, and any of these potential purchasers could determine to purchase mo.